Growth Metrics

Mannkind (MNKD) Research & Development (2010 - 2026)

Mannkind (MNKD) reported Research & Development of $17.2 million for Q1 2026, up 56.33% year-over-year from $11.0 million in Q1 2025, and down 37.54% on a QoQ basis from $27.6 million in Q4 2025.

Mannkind (MNKD) has 17 years of Research & Development data on file, last reported at $17.2 million in Q1 2026.

  • Quarterly Research & Development rose 56.33% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.6 million (up 54.7% YoY) and the FY2025 annual result came in at $66.3 million, up 44.57% from the prior year.
  • Research & Development slipped to $17.2 million in Q1 2026 per MNKD's latest filing, from $27.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $27.6 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
  • The 5-year median for Research & Development is $10.0 million (2024), against an average of $10.6 million.
  • Peak annual rise in Research & Development reached 147.69% in 2025, while the deepest fall reached 8.8% in 2025.
  • Tracing MNKD's Research & Development over 5 years: stood at $7.2 million in 2022, then advanced by 29.07% to $9.2 million in 2023, then climbed by 20.59% to $11.1 million in 2024, then soared by 147.69% to $27.6 million in 2025, then tumbled by 37.54% to $17.2 million in 2026.
  • Per Business Quant, the three latest MNKD Research & Development figures stand at $17.2 million (Q1 2026), $27.6 million (Q4 2025), and $14.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 626,092.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 4.32 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -101.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 1.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 961.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -2.30 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.54 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 364.87 Mn
10 Mannkind 1.09 Bn 956.66 Mn 82.66 Mn 17.23 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 17.23 Mn
Dec 31, 2025 27.59 Mn
Sep 30, 2025 14.06 Mn
Jun 30, 2025 13.68 Mn
Mar 31, 2025 11.02 Mn
Dec 31, 2024 11.14 Mn
Sep 30, 2024 12.93 Mn
Jun 30, 2024 11.82 Mn
Mar 31, 2024 10.01 Mn
Dec 31, 2023 9.24 Mn
Sep 30, 2023 9.99 Mn
Jun 30, 2023 6.45 Mn
Mar 31, 2023 5.61 Mn
Dec 31, 2022 7.16 Mn
Sep 30, 2022 4.14 Mn
Jun 30, 2022 4.89 Mn
Mar 31, 2022 3.54 Mn
Dec 31, 2021 3.89 Mn
Sep 30, 2021 3.66 Mn
Jun 30, 2021 2.33 Mn
Mar 31, 2021 2.44 Mn
Dec 31, 2020 1.55 Mn
Sep 30, 2020 1.48 Mn
Jun 30, 2020 1.46 Mn
Mar 31, 2020 1.76 Mn
Dec 31, 2019 2.02 Mn
Sep 30, 2019 1.58 Mn
Jun 30, 2019 1.63 Mn
Mar 31, 2019 1.67 Mn
Dec 31, 2018 1.08 Mn
Sep 30, 2018 2.04 Mn
Jun 30, 2018 2.97 Mn
Mar 31, 2018 2.64 Mn
Dec 31, 2017 3.51 Mn
Sep 30, 2017 4.36 Mn
Jun 30, 2017 3.12 Mn
Mar 31, 2017 3.13 Mn
Dec 31, 2016 1.56 Mn
Sep 30, 2016 3.92 Mn
Jun 30, 2016 4.31 Mn
Mar 31, 2016 5.13 Mn
Dec 31, 2015 6.22 Mn
Sep 30, 2015 6.34 Mn
Jun 30, 2015 7.74 Mn
Mar 31, 2015 9.38 Mn
Dec 31, 2014 17.56 Mn
Sep 30, 2014 19.18 Mn
Jun 30, 2014 37.32 Mn
Mar 31, 2014 26.18 Mn
Dec 31, 2013 28.99 Mn
Sep 30, 2013 27.28 Mn
Jun 30, 2013 27.05 Mn
Mar 31, 2013 26.40 Mn
Dec 31, 2012 25.28 Mn
Sep 30, 2012 25.45 Mn
Jun 30, 2012 26.64 Mn
Mar 31, 2012 24.16 Mn
Dec 31, 2011 20.24 Mn
Sep 30, 2011 23.13 Mn
Jun 30, 2011 30.30 Mn
Mar 31, 2011 26.29 Mn
Dec 31, 2010 24.22 Mn
Sep 30, 2010 31.41 Mn
Jun 30, 2010 26.16 Mn